{"result": "(\"entity\"<|>PACIENTE<|>PERSON<|>The patient is an individual undergoing treatment for a medical condition, with a history of liver transplant and diabetes management.)\n##\n(\"entity\"<|>CICLOSPORINA<|>ORGANIZATION<|>Ciclosporin is an immunosuppressant medication that was used in the patient's treatment but was later substituted due to side effects.)\n##\n(\"entity\"<|>EVEROLIMUS<|>ORGANIZATION<|>Everolimus is a medication that was introduced to the patient’s treatment regimen after stopping ciclosporin.)\n##\n(\"entity\"<|>HOMOCISTEÍNA<|>ORGANIZATION<|>Homocysteine is an amino acid whose levels were monitored in the patient, indicating a potential health issue.)\n##\n(\"entity\"<|>TROMBOSIS PORTAL<|>EVENT<|>Portal thrombosis is a condition diagnosed in the patient in March 2009, related to their medical history.)\n##\n(\"entity\"<|>AST<|>ORGANIZATION<|>AST (aspartate aminotransferase) is an enzyme whose levels were monitored in the patient as part of their liver function tests.)\n##\n(\"entity\"<|>ALT<|>ORGANIZATION<|>ALT (alanine aminotransferase) is another enzyme monitored in the patient, indicating liver health.)\n##\n(\"entity\"<|>GGT<|>ORGANIZATION<|>GGT (gamma-glutamyl transferase) is an enzyme whose levels were tracked in the patient to assess liver function.)\n##\n(\"entity\"<|>HbA1c<|>ORGANIZATION<|>HbA1c is a measure of blood sugar levels over time, monitored in the patient to manage diabetes.)\n##\n(\"entity\"<|>BMI<|>ORGANIZATION<|>BMI (Body Mass Index) is a measure used to assess the patient's weight relative to height, indicating their nutritional status.)\n##\n(\"entity\"<|>ANALÍTICA<|>EVENT<|>The analytical tests performed on the patient provided insights into their health status and treatment efficacy.)\n##\n(\"entity\"<|>FERROPENIA<|>EVENT<|>Ferropenia refers to iron deficiency detected in the patient during follow-up evaluations.)\n##\n(\"entity\"<|>DEFICIT DE ZINC<|>EVENT<|>Zinc deficiency was identified in the patient, indicating a need for supplementation.)\n##\n(\"entity\"<|>HIPOMAGNESEMIA<|>EVENT<|>Hypomagnesemia, or low magnesium levels, was noted in the patient, requiring attention in their treatment plan.)\n##\n(\"entity\"<|>VITAMINA D<|>ORGANIZATION<|>Vitamin D levels were monitored in the patient, with supplementation added to their treatment regimen.)\n##\n(\"entity\"<|>HIPOCALCEMIA<|>EVENT<|>Hypocalcemia, or low calcium levels, was also noted in the patient, indicating a need for monitoring and potential supplementation.)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: OCINA 900 mg d1-5/6 semanas + ADRIAMICINA\n90 mg iv d1/ 3 semanas recibiendo 3 ciclos de ETZ y 6+2 de ADR hasta junio 2002 mejor\ntolerancia (náuseas/vómitos G1, diarrea G1).\nResultado: Enfermedad Estable (3 mx en RNM de 2, 1 y 0´8 cm respectivamente).\nConsulta de Endocrinología y Nutrición (continuación del seguimiento). Evaluación\nambulatoria.\nEXPLORACIÓN FÍSICA: talla 180,5 cm, peso 70,5 kg, BMI 21,7.\nPeso habitual 82 kg (BMI 25,2). % pérdida de peso 14%.\n\n\n\n                                                                                                  151\n---\n     Actividad física mínima (camina algo a diario). 1-2 deposiciones con esteatorrea.\n     ANALÍTICA: Hb 13,1 GOT 88, GPT 73, GGT 125, Alb 3,6, HbA1c 7,2.\n     En tratamiento con insulina basal, enzimas pancreáticos y suplementos específicos de\n     diabetes y MCT (50ml).\n     Tratamiento tras recidiva (continuación).\n\n\n\n              Julio 2002: se replantea el caso con Cirugía que valoran el trasplante hepático.\n     Metástasis hepáticas técnicamente irresecables y no metástasis a otro nivel en TAC y\n     RMN (no así en octreótide).\n\n\n\n              Septiembre 2002:        se realiza gammagrafía con octreótide donde se observa\n     captación hepática en varios lóbulos y además en hilio pancreático (como en explora-\n     ción previa). Se inicia tratamiento con análogo somatostatina.\n\n\n\n              2/9/2003: TRANSPLANTE HEPÁTICO sin complicaciones.\n\n\n\n              Diciembre      2003:     octreoscan        patológico       (adenopatías        peripancreáticas).\n      Se continúa con análogo de somatostatina.\n\n\n\n              Marzo - abril 2005:       malestar general e ictericia estudiado por Digestivo (no\n     rechazo) HEPATITIS B.\n\n\n\n              Hasta último control al 17/03/08: enfermedad Estable en TAC y octreoscan (adeno-\n     patías peripancreáticas sin cambios) y asintomático. Continúa con análogo.\n     Consulta de Endocrinología y Nutrición (continuación del seguimiento). Evaluación\n     ambulatoria postoperatoria.\n     EXPLORACIÓN FÍSICA: Talla 180,5 cm, peso 71,5 kg, BMI 21,9.\n     Peso habitual 82 kg (BMI 25,2). % pérdida de peso 13%.\n     Actividad física mínima (camina algo a diario). 1-2 deposiciones normales.\n     ANALÍTICA: Hb 12,7 GOT 59, GPT 57, GGT 98, Alb 4,4, HbA1c 7,1, resto normal.\n     En tratamiento con insulina basal, análogos de somatostatina, enzimas pancreáticos y\n     suplementos específicos de diabetes y MCT (80ml).\n     En los controles evolutivos se detectaron ferropenia y déficit de Zinc, hipomagnesemia\n     junto con déficit de vitamina D y tendencia a la hipocalcemia. Se añadieron suplemen-\n     tos de estos minerales y la vitamina D al tratamiento previo.\n     El peso se mantuvo relativamente estable en torno a 70 kg.\n     La deposición era normal.\n     El control glucémico osciló entre unas HbA1c de 6,8 a 7,6% en tratamiento con insulina\n     basal y preprandial solo en la comida con escasas hipoglucemias en relación con ingestas\n     no cumplimentadas.\n\n\n\n152\n---\nEl paciente presentaba astenia crónica y una actividad física limitada a lo largo de\ntodos estos años.\nLos niveles de albúmina se mantuvieron entre 3,9 y 4,6.\n\n\n\n         Seguimiento. Enero 2009: cuadro neurológico que mejora al suspender ciclosporina\ny reaparece al introducirla. Se sustituye por everolimus.\n\n\n\n         Marzo 2009:       encefalopatía intermitente y recurrente. Trombosis portal.\nGlu 75 mg/dl. HbA1c 7.2. Cr. 1.26. AST 113. ALT 125. GGT 87. FA 297. LDH 673. Homocisteína\n25.5 (Se confirma homocigosis C677T del gen Tetra Hidro Folato Reductasa). Amonio 263.\nDiagnóstico: Encefalopatía hiperamonémica por shunt espontáneo en el contexto de\ntrombosis portal.\nConsulta de Endocrinología y Nutrición (continuación\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>OCINA<|>ORGANIZATION<|>OCINA is a medication used in treatment regimens, specifically mentioned in the context of cancer treatment.)\n##\n(\"entity\"<|>ADRIAMICINA<|>ORGANIZATION<|>ADRIAMICINA is a chemotherapy drug used in cancer treatment, administered intravenously.)\n##\n(\"entity\"<|>JULIO 2002<|>EVENT<|>In July 2002, the case was reconsidered for a potential liver transplant due to irresectable hepatic metastases.)\n##\n(\"entity\"<|>SEPTIEMBRE 2002<|>EVENT<|>In September 2002, a gammagraphy with octreotide was performed, showing hepatic uptake in several lobes.)\n##\n(\"entity\"<|>TRANSPLANTE HEPÁTICO<|>EVENT<|>Liver transplant performed on 2nd September 2003 without complications.)\n##\n(\"entity\"<|>DICIEMBRE 2003<|>EVENT<|>In December 2003, a pathological octreoscan indicated peripancreatic adenopathies.)\n##\n(\"entity\"<|>MARZO 2005<|>EVENT<|>In March-April 2005, the patient experienced general malaise and jaundice, studied by Digestive specialists.)\n##\n(\"entity\"<|>ENERO 2009<|>EVENT<|>In January 2009, the patient presented with neurological symptoms that improved upon stopping ciclosporin.)\n##\n(\"entity\"<|>MARCH 2009<|>EVENT<|>In March 2009, the patient experienced intermittent encephalopathy and portal thrombosis.)\n##\n(\"entity\"<|>ENFERMEDAD ESTABLE<|>EVENT<|>The patient's condition was stable as of the last control on 17th March 2008, with no significant changes in adenopathies.)\n##\n(\"entity\"<|>HEPATITIS B<|>EVENT<|>The patient was diagnosed with Hepatitis B in March-April 2005.)\n##\n(\"entity\"<|>INSULINA<|>ORGANIZATION<|>Insulin is a hormone used in the treatment of diabetes, mentioned as part of the patient's ongoing treatment.)\n##\n(\"entity\"<|>ANÁLOGOS DE SOMATOSTATINA<|>ORGANIZATION<|>Somatostatin analogs are medications used to manage certain types of tumors and were part of the patient's treatment.)\n##\n(\"entity\"<|>ENZIMAS PANCREÁTICOS<|>ORGANIZATION<|>Pancreatic enzymes are supplements used to aid digestion, mentioned in the patient's treatment regimen.)\n##\n(\"entity\"<|>SUPLEMENTOS ESPECÍFICOS DE DIABETES<|>ORGANIZATION<|>Specific diabetes supplements are part of the patient's treatment to manage diabetes.)\n##\n(\"entity\"<|>MCT<|>ORGANIZATION<|>MCT refers to medium-chain triglycerides, which are used as dietary supplements in the patient's treatment.)\n##\n(\"entity\"<|>TAC<|>EVENT<|>A CT scan was performed to assess the patient's condition, showing stable disease.)\n##\n(\"entity\"<|>RMN<|>EVENT<|>An MRI was performed to monitor the patient's condition, indicating stable disease.)\n##\n(\"relationship\"<|>ADRIAMICINA<|>OCINA<|>ADRIAMICINA is used in conjunction with OCINA in cancer treatment regimens<|>7)\n##\n(\"relationship\"<|>TRANSPLANTE HEPÁTICO<|>JULIO 2002<|>The liver transplant was reconsidered in July 2002 due to the patient's condition<|>5)\n##\n(\"relationship\"<|>SEPTIEMBRE 2002<|>TRANSPLANTE HEPÁTICO<|>The gammagraphy in September 2002 was part of the follow-up after the liver transplant<|>4)\n##\n(\"relationship\"<|>DICIEMBRE 2003<|>TRANSPLANTE HEPÁTICO<|>The pathological octreoscan in December 2003 was related to the patient's post-transplant condition<|>4)\n##\n(\"relationship\"<|>MARZO 2005<|>TRANSPLANTE HEPÁTICO<|>The general malaise and jaundice in March-April 2005 were evaluated in the context of the liver transplant<|>4)\n##\n(\"relationship\"<|>ENERO 2009<|>TRANSPLANTE HEPÁTICO<|>The neurological symptoms in January 2009 were assessed in relation to the patient's history of liver transplant<|>4)\n##\n(\"relationship\"<|>MARCH 2009<|>TRANSPLANTE HEPÁTICO<|>The patient's encephalopathy in March 2009 was linked to complications following the liver transplant<|>4)\n##\n(\"relationship\"<|>INSULINA<|>ANÁLOGOS DE SOMATOSTATINA<|>Insulin and somatostatin analogs are both part of the patient's diabetes management regimen<|>6)\n##\n(\"relationship\"<|>ENZIMAS PANCREÁTICOS<|>SUPLEMENTOS ESPECÍFICOS DE DIABETES<|>Pancreatic enzymes and specific diabetes supplements are both included in the patient's treatment plan<|>6)\n##\n(\"relationship\"<|>MCT<|>SUPLEMENTOS ESPECÍFICOS DE DIABETES<|>MCT is used as a dietary supplement alongside specific diabetes supplements in the patient's treatment<|>6)\n<|COMPLETE|>"}]}